Lung cancer is one of the deadliest diseases, not only due to its high mortality rate but also because of the difficulty in detecting it at an early stage. This is where artificial intelligence emerges as a game-changing tool. In an interview with Dr. Pavel Špás, pneumologist at OTRAN Kutná Hora, we explored the possibilities and benefits of using AI in lung cancer diagnostics.
“If a routine chest X-ray from a patient with lung cancer were evaluated by artificial intelligence, the lesion could be identified earlier, potentially saving the patient’s life,” says Dr. Pavel Špás.
According to him, artificial intelligence can be critical not only in quickly detecting pathological findings but also in alleviating the workload of physicians who face an increasing volume of patients and complex diagnostics. Automated systems can help identify subtle abnormalities that might be missed at first glance, giving doctors more time to provide personalized care to patients.
Another key aspect highlighted by Dr. Špás is the psychological demand of a radiologist’s work. “Every day, you need to make decisions quickly and accurately. Technologies like AI can help reduce this burden and ensure that patients receive the best possible care,” he adds.
Early detection of lung cancer is also the focus of a pilot programme by Carebot and global biopharmaceutical company Bristol Myers Squibb. This innovative partnership will enable the integration of Carebot's solution, which assists physicians in the evaluation of X-ray images, to increase diagnostic accuracy and speed up the identification of early stages of lung cancer.
The interview with Dr. Pavel Špás is part of the “AI in the Hands of Doctors” series, which we bring to showcase how modern technology is transforming healthcare practice. You can watch the full video on our website.
